{"id":1152,"date":"2023-02-01T19:32:34","date_gmt":"2023-02-01T19:32:34","guid":{"rendered":"https:\/\/blog.trive.com\/?p=1152"},"modified":"2023-02-09T12:56:51","modified_gmt":"2023-02-09T12:56:51","slug":"gloom-for-pfizer-nyse-pfe-despite-delivering-best-revenues-ever","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","title":{"rendered":"Pesimismo para Pfizer (NYSE: PFE) a pesar de generar los mejores ingresos de la historia"},"content":{"rendered":"<p>Pfizer registr\u00f3 sus mejores ingresos en un a\u00f1o, generando un ingreso estelar de $100B, un rotundo aumento de 23% con respecto al a\u00f1o anterior. El crecimiento de los ingresos estuvo impulsado en gran medida por las ventas de tratamientos contra el covid-19, dos de los cuales son los productos m\u00e1s demandados de Pfizer, Comirnaty (una vacuna contra el covid) y Paxlovid (un medicamento antiviral), respectivamente.<\/p>\n\n\n\n<p>A pesar de los ingresos r\u00e9cord, las perspectivas de Pfizer para 2023 se ven empa\u00f1adas por una era posterior a la pandemia caracterizada por una disminuci\u00f3n de las infecciones, lo que provoc\u00f3 una menor demanda de vacunas. Esto se ha reflejado en los aspectos financieros destacados de Pfizer para 2023, con una expectativa de una disminuci\u00f3n en los ingresos entre 29% y 33% a $67B para el a\u00f1o. Una ca\u00edda en los ingresos puede traducirse potencialmente en una ca\u00edda en las ganancias por acci\u00f3n, dejando el precio de las acciones de Pfizer en una posici\u00f3n precaria para 2023.<\/p>\n\n\n\n<h2>An\u00e1lisis T\u00e9cnico<\/h2>\n\n\n\n<p>Actualmente, el precio ha tenido una tendencia bajista y cotiza cerca de los m\u00ednimos de octubre de 2022, con soporte en el nivel $41.52. La resistencia se form\u00f3 en el nivel $55, acompa\u00f1ada de un fuerte impulso bajista. La tendencia a la baja se debi\u00f3 principalmente a menores ingresos y expectativas de ganancias para 2023.<\/p>\n\n\n\n<p>El resultado de ganancias mejor de lo esperado proporcion\u00f3 una sacudida en la acci\u00f3n del precio ya que los traders reaccionaron positivamente al resultado. Apoyado por la vela envolvente formada despu\u00e9s de la publicaci\u00f3n de ganancias, si los operadores alcistas contin\u00faan con grandes vol\u00famenes, es probable que el precio contin\u00fae subiendo con un objetivo potencial en el nivel de resistencia $55 por acci\u00f3n.<\/p>\n\n\n\n<p>Sin embargo, si los inversores bajistas encuentran pesimismo en el precio actual con respecto a una perspectiva sombr\u00eda, es probable que el precio regrese al soporte en el nivel $41.52.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"1024\" height=\"520\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1024x520.png\" alt=\"\" class=\"wp-image-1153\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1024x520.png 1024w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-300x152.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-768x390.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1536x780.png 1536w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-18x9.png 18w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e.png 1834w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2>An\u00e1lisis Fundamental<\/h2>\n\n\n\n<p>Las ventas de vacunas Covid de $38B constituyeron la mayor\u00eda de los ingresos para 2023. La mejora en las ventas produjo un crecimiento anual de 43% en ingresos netos, de $21,979B a $31,372B. Excluyendo los tratamientos de covid-19, el crecimiento del a\u00f1o fue de apenas 2%, lo que refleja la gran importancia de las ventas relacionadas con la pandemia para Pfizer.<\/p>\n\n\n\n<p>Las vacunas anticipadas de Pfizer para la poblaci\u00f3n de EE. UU. en 2023 son 24%, una disminuci\u00f3n con respecto a las 31% registradas en 2022. Esto refleja el debilitamiento de la demanda de tratamiento de la COVID-19 a medida que el mundo se aleja de la era de la pandemia. Es probable que esto cause un da\u00f1o significativo a la l\u00ednea superior, como se refleja en los aspectos financieros destacados de Pfizer.<\/p>\n\n\n\n<p>Despu\u00e9s de descontar los flujos de efectivo futuros, se obtuvo un valor intr\u00ednseco de $52 por acci\u00f3n. El precio actual de las acciones cotiza con descuento y puede proporcionar un movimiento alcista a corto plazo.<\/p>\n\n\n\n<h2>Resumen<\/h2>\n\n\n\n<p>Seg\u00fan el valor intr\u00ednseco calculado, Pfizer tiene cierto margen de mejora a corto y medio plazo. Sin embargo, es probable que el movimiento alcista se deshaga por la disminuci\u00f3n de las ventas y las ganancias para 2023, especialmente en los segmentos relacionados con la pandemia, acompa\u00f1ado de una posible recesi\u00f3n leve.<\/p>","protected":false},"excerpt":{"rendered":"<p>Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]<\/p>","protected":false},"author":8,"featured_media":1155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog\" \/>\n<meta property=\"og:description\" content=\"Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T19:32:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-09T12:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/pfizezr_en.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1022\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever\",\"datePublished\":\"2023-02-01T19:32:34+00:00\",\"dateModified\":\"2023-02-09T12:56:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\",\"url\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\",\"name\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-02-01T19:32:34+00:00\",\"dateModified\":\"2023-02-09T12:56:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/es\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","og_locale":"es_ES","og_type":"article","og_title":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","og_description":"Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]","og_url":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","og_site_name":"Trive Blog","article_published_time":"2023-02-01T19:32:34+00:00","article_modified_time":"2023-02-09T12:56:51+00:00","og_image":[{"width":1022,"height":512,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/pfizezr_en.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"},"author":{"name":"","@id":""},"headline":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever","datePublished":"2023-02-01T19:32:34+00:00","dateModified":"2023-02-09T12:56:51+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","url":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","name":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-02-01T19:32:34+00:00","dateModified":"2023-02-09T12:56:51+00:00","breadcrumb":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/es\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1152"}],"collection":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/comments?post=1152"}],"version-history":[{"count":1,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1152\/revisions"}],"predecessor-version":[{"id":1154,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1152\/revisions\/1154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/media\/1155"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/media?parent=1152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/categories?post=1152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/tags?post=1152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}